SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE

1 . (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide characterized as crystalline Form A.

2 . Form A of claim 1 , wherein the Form A is characterized by one or more peaks at 19.3 to 19.7 degrees, 21.5 to 21.9 degrees, and 16.9 to 17.3 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.

3 . Form A of claim 2 , wherein the Form A is characterized by one or more peaks at about 19.5, 21.7, and 17.1 degrees.

4 . Form A of claim 3 , wherein the Form A is further characterized by a peak at 20.2 to 20.6 degrees.

5 . Form A of claim 4 , wherein the Form A is further characterized by a peak at about 20.4 degrees.

6 . Form A of claim 5 , wherein the Form A is further characterized by a peak at 18.6 to 19.0 degrees.

7 . Form A of claim 6 , wherein the Form A is further characterized by a peak at about 18.8 degrees.

8 . Form A of claim 7 , wherein the Form A is further characterized by a peak at 24.5 to 24.9 degrees.

9 . Form A of claim 8 , wherein the Form A is further characterized by a peak at about 24.7 degrees.

10 . Form A of claim 9 , wherein the Form A is further characterized by a peak at 9.8 to 10.2 degrees.

11 . Form A of claim 10 , wherein the Form A is further characterized by a peak at about 10.0 degrees.

12 . Form A of claim 11 , wherein the Form A is further characterized by a peak at 4.8 to 5.2 degrees.

13 . Form A of claim 12 , wherein the Form A is further characterized by a peak at about 5.0 degrees.

14 . Form A of claim 13 , wherein the Form A is further characterized by a peak at 24.0 to 24.4 degrees.

15 . Form A of claim 14 , wherein the Form A is further characterized by a peak at about 24.2 degrees.

16 . Form A of claim 15 , wherein the Form A is further characterized by a peak at 18.3 to 18.7 degrees.

17 . Form A of claim 16 , wherein the Form A is further characterized by a peak at about 18.5 degrees.

18 . Form A of claim 1 , wherein the Form A is characterized by a diffraction pattern substantially similar to that of FIG. 4 .

19 . Form A of claim 1 , wherein the Form A is characterized by a diffraction pattern substantially similar to that of FIG. 5 .

20 . A crystal form of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide having a monoclinic crystal system, a C2 space group, and the following unit cell dimensions:

a=21.0952(16) Å α=90°

b=6.6287(5) Å β= 95 . 867 (6)°

c=17.7917(15) Å γ=90°.

21 . A pharmaceutical composition comprising Form A of claim 1 , and a pharmaceutically acceptable carrier.

22 . The pharmaceutical composition of claim 21 , further comprising an additional therapeutic agent.

23 . The pharmaceutical composition of claim 22 , wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR potentiator, or a nutritional agent.

24 . A process of preparing the Form A of claim 1 comprising slurrying (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide in a solvent for an effective amount of time.

25 . The process of claim 24 , wherein the solvent is ethyl acetate, dichloromethane, MTBE, isopropyl acetate, water/ethanol, water/acetonitrile, water/methanol, or water/isopropyl alcohol.

26 . The process of claim 24 or 25 , wherein the effective amount of time is 24 hours to 2 weeks.

27 . A process of preparing the Form A of claim 1 comprising dissolving (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide in a solvent and evaporating the solvent.

28 . The process of claim 27 , wherein the solvent is acetone, acetonitrile, methanol, or isopropyl alcohol.

29 . A process of preparing the Form A of claim 1 comprising dissolving (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide in a first solvent and adding a second solvent that (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide is not soluble in.

30 . The process of claim 29 , wherein the first solvent is ethyl acetate, ethanol, isopropyl alcohol, or acetone.

31 . The process of claim 29 or 30 , wherein the second solvent is heptane or water.

32 . The process of claim 29 , wherein the addition of the second solvent is done while stirring the solution of the first solvent and (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide.

33 . Solid substantially amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide.

34 . The amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide of claim 33 , comprising less than about 5% crystalline (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide.

35 . A pharmaceutical composition comprising the amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide of claim 33 and a pharmaceutically acceptable carrier.

36 . The pharmaceutical composition of claim 35 , further comprising an additional therapeutic agent.

37 . The pharmaceutical composition of claim 36 , wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR potentiator, or a nutritional agent.

38 . A process of preparing the amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide of claim 33 or 34 comprising dissolving (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide in a suitable solvent and removing the solvent by rotary evaporation.

39 . The process of claim 38 , wherein the solvent is methanol.

40 . A solid dispersion comprising the amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide of claim 33 and a polymer.

41 . The solid dispersion of claim 40 , wherein the polymer is hydroxypropylmethylcellulose (HPMC).

42 . The solid dispersion of claim 40 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS).

43 . The solid dispersion of claim 40 , wherein the polymer is present in an amount from 10% by weight to 80% by weight.

44 . The solid dispersion of claim 40 , wherein the polymer is present in an amount from 30% by weight to 60% by weight.

45 . The solid dispersion of claim 40 , wherein the polymer is present in an amount of about 49.5% by weight.

46 . The solid dispersion of claim 40 , wherein the (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide is present in an amount from 10% by weight to 80% by weight.

47 . The solid dispersion of claim 40 , wherein the (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide is present in an amount from 30% by weight to 60% by weight.

48 . The solid dispersion of claim 40 , wherein the (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide is present in an amount of about 50% by weight.

49 . The solid dispersion of claim 40 , further comprising a surfactant.

50 . The solid dispersion of claim 49 , wherein the surfactant is sodium lauryl sulfate.

51 . The solid dispersion of claim 49 , wherein the surfactant is present in an amount from 0.1% by weight to 5% by weight.

52 . The solid dispersion of claim 49 , wherein the surfactant is present in an amount of about 0.5% by weight.

53 . The solid dispersion of claim 49 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS) in the amount of 49.5% by weight, the surfactant is sodium lauryl sulfate in the amount of 0.5% by weight, and the (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide is present in the amount of 50% by weight.

54 . A pharmaceutical composition comprising the solid dispersion of claim 40 and a pharmaceutically acceptable carrier.

55 . The pharmaceutical composition of claim 54 , further comprising an additional therapeutic agent.

56 . The pharmaceutical composition of claim 55 , wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR potentiator, or a nutritional agent.

57 . A process of preparing amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide comprising spray drying (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide.

58 . The process of claim 57 , comprising combining (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and a suitable solvent and then spray drying the mixture to obtain amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide.

59 . The process of claim 58 , wherein the solvent is an alcohol.

60 . The process of claim 58 , wherein the solvent is methanol.

61 . The process of claim 57 , comprising:

a) forming a mixture comprising (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, a polymer, and a solvent; and

b) spray drying the mixture to form a solid dispersion.

62 . The process of claim 61 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS).

63 . The process of claim 61 , wherein the polymer is in an amount of from 10% by weight to 80% by weight of the solid dispersion.

64 . The process of claim 61 , wherein the polymer is in an amount of about 49.5% by weight of the solid dispersion.

65 . The process of claim 61 , wherein the solvent is methanol.

66 . The process of claim 61 , wherein the mixture further comprises a surfactant.

67 . The process of claim 66 , wherein the surfactant is sodium lauryl sulfate (SLS).

68 . The process of claim 66 , wherein the surfactant is in an amount of from 0.1% bby weight to 5% by weight of the solid dispersion.

69 . The process of claim 66 , wherein the surfactant is in an amount of about 0.5% by weight of the solid dispersion.

70 . The process of claim 61 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS) in the amount of about 49.5% by weight of the solid dispersion, the solvent is methanol, and the mixture further comprises sodium lauryl sulfate in an amount of about 0.5% by weight of the solid dispersion.

71 . A method of treating a CFTR mediated disease in a subject comprising administering to the subject an effective amount of Form A of claim 1 , the amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide of claim 33 , or the solid dispersion of claim 40 .

72 . The method of claim 71 , wherein the CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility, mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, polyglutamine neurological disorders, Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, myotonic dystrophy, spongiform encephalopathies, hereditary Creutzfeldt-Jakob disease, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies, myotonia congenita, Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, Primary Ciliary Dyskinesia (PCD), inherited disorders of the structure and/or function of cilia, PCD with situs inversus, PCD without situs inversus, or ciliary aplasia.

73 . The method of claim 71 , wherein the CFTR mediated disease is selected from cystic fibrosis, COPD, osteoporosis, dry-eye disease, or emphysema.

74 . The method of claim 71 , wherein the CFTR mediated disease is cystic fibrosis.

75 . The method of claim 71 , wherein the subject has cystic fibrosis transmembrane receptor (CFTR) with a ΔF508 mutation.

76 . The method of claim 71 , wherein the subject has cystic fibrosis transmembrane receptor (CFTR) with a R117H mutation.

77 . The method of claim 71 , wherein the subject has cystic fibrosis transmembrane receptor (CFTR) with a G551D mutation.

78 . The method of claim 71 , wherein the method comprises administering an additional therapeutic agent.

79 . The method of claim 78 , wherein the therapeutic agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR potentiator, or a nutritional agent.